Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
A phase 1/2 trial of Eflornithine, Fulvestrant, Capivasertib in melanoma and skin cancer, run by Aminex Therapeutics, Inc., now recruiting.
Overview
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07287917 by Aminex Therapeutics, Inc., with 92 participants planned, started 2026-01-26 and due to reach its primary completion in 2028-02-28. Interventions recorded: AMXT 1501 Dicaprate, DFMO, Fulvestrant, Capivasertib, Pembrolizumab. Conditions listed: Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialCapivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
Shares Capivasertib, Fulvestrant.
- TrialA Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain
Shares Capivasertib, Fulvestrant.
- TrialA Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
Shares Skin cancer (all types), Melanoma.
- TrialCapivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Shares Capivasertib, Fulvestrant.
- TrialStudy of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
Shares Skin cancer (all types), Melanoma.
- TrialCAPItello-291
Shares Capivasertib, Fulvestrant.
- PairingPI3K/AKT-pathway inhibitor + endocrine therapy (± CDK4/6)
Shares Capivasertib, Fulvestrant.
- PathwayChemical carcinogenesis - receptor activation
Shares Capivasertib, Fulvestrant.